Mackenzie Financial Corp Ligand Pharmaceuticals Inc Transaction History

Mackenzie Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$89.56 - $126.72 $226,049 - $319,841	-2,524 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$68.28 - $123.65 $1.55 Million - $2.81 Million	-22,756 Reduced 90.02%	2,524 $282,000
Q1 2020 May 14, 2020	BUY	$63.37 - $107.88 $1.6 Million - $2.73 Million	25,280 New	25,280 $1.84 Million
Q1 2019 May 15, 2019	SELL	$105.93 - $142.47 $2.32 Million - $3.12 Million	-21,887 Closed	0 $0
Q4 2018 Feb 06, 2019	SELL	$128.36 - $272.13 $1.82 Million - $3.87 Million	-14,215 Reduced 39.37%	21,887 $2.97 Million
Q3 2018 Nov 15, 2018	BUY	$211.18 - $274.49 $7.62 Million - $9.91 Million	36,102 New	36,102 $9.91 Million

277

18.5M

30.8K

5.2K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.82B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.